Sample time / Initial
(n = 48) / 43
(2 – 367) / p = 0.817 / 778
(40 – 47928) / p = 0.078 / 43
(0.3 – 11779) / p = 0.325 / 405
(156 – 1849) / p = 0.235 / 19
(5 – 479) / p = 0.606
Recurrence
(n = 22) / 40
(1 – 163) / 4051
(12 – 40925) / 147
(0.1 – 4210) / 441
(257 – 2001) / 15.5
(4 – 56)
Previousperitonealsurgery / No
(n = 37) / 41
(1 – 367) / p = 0.605 / 3589
(12 – 47928) / p = 0.003 / 136
(0.1 – 11779) / p = 0.019 / 433.5
(210 – 2001) / p = 0.361 / 20.5
(6 – 56) / p = 0.274
Yes
(n = 33) / 43
(2 – 178) / 383
(40 – 19614) / 35
(0.3 – 3755) / 406
(156 – 1849) / 17
(4 – 479)
Previous
HIPEC* / No
(n = 16) / 31.5
(1 – 134) / p = 0.322 / 2188
(12 – 20885) / p = 0.017 / 32.5
(0.1 – 4210) / p = 0.048 / 425
(257 – 749) / p = 0.033 / 15
(4 – 56) / p = 0.159
Yes
(n = 5) / 48
(18 – 97) / 15480
(4000 – 40925) / 300
(80 – 1695) / 576
(441 – 2001) / 26
(13 – 40)
Previouschemotherapy* / No
(n = 11) / 38
(4 – 72) / p = 0.673 / 3293
(23 – 20885) / p = 0.573 / 164
(5 – 4210) / p = 0.725 / 425.5
(257 – 749) / p = 0.257 / 15
(10 – 56) / p = 0.972
Yes
(n = 10) / 37.5
(1 – 134) / 4777
(12 – 40925) / 105.5
(0.1 – 1695) / 477
(275 – 2001) / 18
(4 – 38)
Supplementary Table 3: Influence of cancer patient characteristics on peritoneal cytokines levels (n = 70)
*: these variableswere only available in 21 the 22 patients managed because of disease recurrence
HIPEC: hyperthermicintraperitonealchemotherapy